Revelation Biosciences Stock (NASDAQ:REVB)

Ownership Financials Chart

Previous Close

$1.35

52W Range

$1.19 - $44.77

50D Avg

$2.23

200D Avg

$6.50

Market Cap

$1.82M

Avg Vol (3M)

$671.40K

Beta

-0.13

Div Yield

REVB Company Profile

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Nov 17, 2020

Website

REVB Performance

REVB Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-9.07B	$-7.98M	$-8.66M
Net Income	$-14.87B	$-15.04M	$-120.25K
EBITDA	$-9.07B	$-7.95M	$-8.63M
Basic EPS	$-23.95	$-87.68	$-8.41
Diluted EPS	$-23.95	$-87.68	$-8.41

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
PBM	Psyence Biomedical Ltd.
SPRC	SciSparc Ltd.
GTBP	GT Biopharma, Inc.
ONCO	Onconetix, Inc.
SLXN	Silexion Therapeutics Ltd.
INDP	Indaptus Therapeutics, Inc.